ATF2抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using ATF2 mouse mAb against NIH/3T3 cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human lung cancer (left) and brain tissues (right) using ATF2 mouse mAb with DAB staining.    

  
  

The ATF2 (Activating Transcription Factor 2) antibody is a tool used to detect and study the ATF2 protein, a member of the basic leucine zipper (bZIP) family of transcription factors. ATF2 plays a dual role in cellular processes, acting as both a transcriptional activator and repressor. It is involved in stress responses, DNA damage repair, cell proliferation, and apoptosis. ATF2 binds to consensus cAMP-responsive elements (CRE) in DNA, often forming homodimers or heterodimers with other bZIP proteins like c-Jun, to regulate target gene expression. Its activity is modulated by post-translational modifications, particularly phosphorylation by stress-activated kinases (e.g., JNK, p38 MAPK), which enhance its transcriptional activity.

ATF2 antibodies are widely used in research to investigate its expression, localization, and activation status in various contexts, including cancer, neurodegeneration, and immune responses. For example, phosphorylated ATF2 (at Thr69/71) is a marker of its activated form, linking it to pathways like MAPK signaling. Dysregulation of ATF2 has been implicated in tumor progression, metastasis, and resistance to therapy, making it a potential biomarker or therapeutic target. These antibodies are validated for techniques like Western blotting, immunohistochemistry, immunofluorescence, and chromatin immunoprecipitation (ChIP). Researchers rely on their specificity to dissect ATF2's context-dependent roles, which can vary between pro-survival and pro-apoptotic functions depending on cellular conditions.